Arbitrage Crypto Trader gives possibility of a convenient inter-exchange arbitrage trade. You do not have to hire programmers to write bots for automatic trading, make up TK for them and try to explain what you need. The convenient interface of the program will help you to trade in a manual mode, as exchanges differ in design and functionality, which sometimes makes it difficult to create quick orders.<br/><br/>Besides, a price difference is displayed all the time, helping you make fast decisions. Additional trading functionality in 1 click and auto trade will become a wonderful assistant for the inter-exchange arbitrage trade.

ArbitrageCT

Trading cryptocurrency terminal for trading on two exchanges simultaneously.

CryptoRank Premium

Add New {name} Alert

Moves above

Moves below

Coin tracking

ATH Reached

change abs

change %

Price Range

Unusual volume

Please connect your account to our Telegram bot to receive notifications

New price alert added

Check your email

We've sent you an email with confirmation link. If you don't have it in your inbox - check your spam box.

CryptoRank App

See CryptoRank with...

You need to click on the button below and start the opened bot

Choose a convenient way to connect your EVM wallet.

Privacy & Terms Agreement

Market Data API

Track your wallet balances, view asset allocations, get real-time price data, and more

Easily manage your assets with our Mobile App

Join and earn by referring new subscribers!

Explore blockchain platforms: ecosystem projects, TVL, and other key metrics

Name

Complete tasks and earn rewards

CryptoRank Spaceships

Select Websites channels that you want to add to Cryptonews feed

Select Sources

Please enter your valid email address to proceed with registration.

Sorry, but your {social} account doesn't have an email address.

IDO/ICO analytics: post-listing ROI and launchpad comparisons.

Track project announcements and campaigns. Spot early opportunities so you don’t miss airdrops and rewards.

Exchanges overview: volumes, listings, market share.

Track rounds, stages, and amounts. See investors and fund portfolios.

Monitor DeFi & NFT, positions and P&L. Popular chains and a mobile app supported.

Lite gives core tools ad-free. Premium adds advanced analytics, full tables, and exclusives.

TGE calendar and vesting flow. Analyze unlock volumes and percentages to gauge supply pressure and plan your moves.

Get in touch with us for info about listings, tokens, exchanges, IDOs, or any other promotional inquires

Interested in a partnership?

Improves token ranking and increases exposure.

Visibility Boost

Accelerates momentum and helps stay in trending.

Trending Score Growth

Boost Benefits

Boost visibility, raise the Trending Score, and unlock the Premium Ticker for {symbol}!

Purchasing a Boost does not guarantee a specific ranking or position. CryptoRank makes no representations or guarantees regarding the impact of Boost on asset visibility. All purchases are final and non-refundable.

Want to learn more about Boost? <link>Check out the guide!</link>

Give {name} a {boost}

Subject

The account is suspected of violating CryptoRank.io terms of use. You may continue to use the website except for personal features.

Your account has been suspended

By accessing and using our Site, you confirm that you are at least 18 years old or the legal age of majority in your jurisdiction. Please also ensure you have read and agree to our Terms of Use and Privacy Policy & Cookies Statement

Stay updated with the latest news, social media updates, and information about %name%. Gain valuable insights into market trends and stay informed about the vibrant community discussions.

%name%: Latest News, Social Media Updates and Insights

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) tumbled by more than 56% on Wednesday after the company reported interim results from its Phase 2 study of ARCT-032, an inhaled mRNA therapy for cystic fibrosis (CF), that failed to show meaningful improvement in lung function. The sharp selloff reflects investor disappointment with the preliminary efficacy […]

Invezz

Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results

ArbitrageCTARCT

Latest ArbitrageCT News and Social Media Feed

Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results